WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2024)
Top general drug manufacturer stocks in 2024 ranked by overall Zen Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

Industry: Drug Manufacturers - Gene...
OverviewZen ScorePriceValuationFinancialsForecastEarnings & RevenueDividendsOwnership
Technicals
Ticker
Company
Country
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
BMY
BRISTOL MYERS SQUIBB CO
United States
$98.10B2,022,193,41176.46%0.36%Net SellingNet Selling
JNJ
JOHNSON & JOHNSON
United States
$355.51B2,408,767,22869.52%0.19%Net SellingNet Selling
GILD
GILEAD SCIENCES INC
United States
$84.40B1,245,774,61683.54%1.09%Net SellingNet Selling
AZN
ASTRAZENECA PLC
United Kingdom
$213.09B1,550,162,62631.49%0.00%
SNY
SANOFI
France
$116.97B1,264,799,96919.51%0.00%
GSK
GSK PLC
United Kingdom
$82.13B4,056,000,0007.26%0.00%
NVS
NOVARTIS AG
Switzerland
$192.98B2,044,033,9866.92%0.00%
BIIB
BIOGEN INC
United States
$28.61B145,360,79887.86%2.11%Net SellingNet Selling
LLY
ELI LILLY & CO
United States
$713.35B950,164,45282.44%11.18%Net SellingNet Selling
PFE
PFIZER INC
United States
$146.31B5,646,778,42568.45%0.27%Net SellingNet Selling
AMGN
AMGEN INC
United States
$142.29B535,918,90176.49%1.01%Net SellingNet Selling
MRK
MERCK & CO INC
United States
$319.59B2,532,643,87276.17%0.19%Net BuyingNet Buying
ABBV
ABBVIE INC
United States
$285.59B1,766,473,35970.16%0.15%Net SellingNet Selling
GRFS
GRIFOLS SA
United States
$4.50B687,554,90817.73%0.00%
AMRN
AMARIN CORP PLC
Ireland
$377.41M410,671,80022.86%15.41%Net SellingNet Selling
OGN
ORGANON & CO
United States
$4.53B255,638,25677.39%0.19%Net SellingNet Selling
SCLX
SCILEX HOLDING CO
United States
$212.72M166,189,83515.74%37.69%
1

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) is the top general drug manufacturer stock with a Zen Score of 68, which is 25 points higher than the general drug manufacturer industry average of 43. It passed 25 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock lose -31.29% over the past year, underperforming other general drug manufacturer stocks by -42 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $56.00, an upside of 15.44% from Bristol Myers Squibb Co's current stock price of $48.51.

Bristol Myers Squibb Co stock has a consensus Hold recommendation according to Wall Street analysts. Of the 12 analysts covering Bristol Myers Squibb Co, 8.33% have issued a Strong Buy rating, 0% have issued a Buy, 83.33% have issued a hold, while 0% have issued a Sell rating, and 8.33% have issued a Strong Sell.

2. Johnson & Johnson (NYSE:JNJ)


Johnson & Johnson (NYSE:JNJ) is the second best general drug manufacturer stock with a Zen Score of 60, which is 17 points higher than the general drug manufacturer industry average of 43. It passed 22 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock lose -10.91% over the past year, underperforming other general drug manufacturer stocks by -22 percentage points.

Johnson & Johnson has an average 1 year price target of $180.50, an upside of 22.3% from Johnson & Johnson's current stock price of $147.59.

Johnson & Johnson stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Johnson & Johnson, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Gilead Sciences (NASDAQ:GILD)


Gilead Sciences (NASDAQ:GILD) is the third best general drug manufacturer stock with a Zen Score of 56, which is 13 points higher than the general drug manufacturer industry average of 43. It passed 20 out of 38 due diligence checks and has strong fundamentals. Gilead Sciences has seen its stock lose -18.99% over the past year, underperforming other general drug manufacturer stocks by -30 percentage points.

Gilead Sciences has an average 1 year price target of $82.88, an upside of 22.32% from Gilead Sciences's current stock price of $67.75.

Gilead Sciences stock has a consensus Hold recommendation according to Wall Street analysts. Of the 8 analysts covering Gilead Sciences, 12.5% have issued a Strong Buy rating, 12.5% have issued a Buy, 75% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 12 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)


Pfizer (NYSE:PFE) has an annual dividend yield of 6.37%, which is 3 percentage points higher than the general drug manufacturer industry average of 3.41%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 434.2% indicates that its high dividend yield might not be sustainable for the long-term.

2. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 4.82%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.41%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of 59.5% indicates that its high dividend yield is sustainable for the long-term.

3. Gilead Sciences (NASDAQ:GILD)


Gilead Sciences (NASDAQ:GILD) has an annual dividend yield of 4.46%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.41%. Gilead Sciences's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Gilead Sciences's dividend has shown consistent growth over the last 10 years.

Gilead Sciences's dividend payout ratio of 66.1% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -0.15% in the last day, and down -2.75% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are down.

What are the most undervalued general drug manufacturer stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

1. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Sanofi has a valuation score of 86, which is 37 points higher than the general drug manufacturer industry average of 49. It passed 6 out of 7 valuation due diligence checks.

Sanofi's stock has dropped -17.28% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -28 percentage points.

2. Astrazeneca (NASDAQ:AZN)


Astrazeneca (NASDAQ:AZN) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Astrazeneca has a valuation score of 71, which is 22 points higher than the general drug manufacturer industry average of 49. It passed 5 out of 7 valuation due diligence checks.

Astrazeneca's stock has dropped -6.65% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -18 percentage points.

3. Gsk (NYSE:GSK)


Gsk (NYSE:GSK) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Gsk has a valuation score of 71, which is 22 points higher than the general drug manufacturer industry average of 49. It passed 5 out of 7 valuation due diligence checks.

Gsk's stock has gained 8.32% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -3 percentage points.

Are general drug manufacturer stocks a good buy now?

47.06% of general drug manufacturer stocks rated by analysts are a buy right now. On average, analysts expect general drug manufacturer stocks to rise by 16.39% over the next year.

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 154.44x.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.